Guggenheim Reaffirms Buy Rating for Tarsus Pharmaceuticals (NASDAQ:TARS)

Tarsus Pharmaceuticals (NASDAQ:TARS)‘s stock had its “buy” rating restated by Guggenheim in a research note issued to investors on Monday,Benzinga reports.

A number of other research analysts also recently weighed in on TARS. The Goldman Sachs Group lifted their price target on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a report on Friday, November 15th. Barclays boosted their price target on Tarsus Pharmaceuticals from $60.00 to $62.00 and gave the company an “overweight” rating in a research note on Monday, January 27th. Finally, Oppenheimer raised their price target on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, January 22nd. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $56.00.

Tarsus Pharmaceuticals Price Performance

Shares of NASDAQ:TARS opened at $52.48 on Monday. The company has a market capitalization of $2.01 billion, a PE ratio of -13.77 and a beta of 1.01. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. The stock has a fifty day moving average of $52.01 and a 200-day moving average of $40.87. Tarsus Pharmaceuticals has a one year low of $20.08 and a one year high of $57.28.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Large investors have recently modified their holdings of the business. Jennison Associates LLC raised its position in shares of Tarsus Pharmaceuticals by 14.8% during the fourth quarter. Jennison Associates LLC now owns 2,500,132 shares of the company’s stock worth $138,432,000 after purchasing an additional 321,552 shares during the period. Assenagon Asset Management S.A. boosted its position in shares of Tarsus Pharmaceuticals by 0.5% during the fourth quarter. Assenagon Asset Management S.A. now owns 1,146,812 shares of the company’s stock valued at $63,499,000 after buying an additional 5,565 shares during the last quarter. Ikarian Capital LLC grew its holdings in Tarsus Pharmaceuticals by 28.7% during the third quarter. Ikarian Capital LLC now owns 1,030,277 shares of the company’s stock worth $33,886,000 after buying an additional 230,000 shares in the last quarter. Geode Capital Management LLC raised its position in Tarsus Pharmaceuticals by 8.1% in the 3rd quarter. Geode Capital Management LLC now owns 835,790 shares of the company’s stock valued at $27,494,000 after buying an additional 62,555 shares during the last quarter. Finally, Lord Abbett & CO. LLC grew its stake in shares of Tarsus Pharmaceuticals by 28.4% in the 3rd quarter. Lord Abbett & CO. LLC now owns 594,876 shares of the company’s stock worth $19,565,000 after acquiring an additional 131,636 shares in the last quarter. Institutional investors own 90.01% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.